查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1610030

非酒精性脂肪性肝炎臨床試驗市場規模、佔有率和趨勢分析報告：按階段、研究設計、地區和細分市場預測，2025-2030

Non-alcoholic Steatohepatitis Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

非酒精性脂肪性肝炎臨床試驗市場成長與趨勢

Grand View Research, Inc.最新報告顯示，預計到2030年，全球非酒精性脂肪性肝炎臨床試驗市場規模將達到41.4億美元，2025年至2030年複合年成長率為6.26%。醫療成本上升、肥胖病例和非酒精性脂肪性肝炎（NASH）的流行是推動該市場成長的因素。 COVID-19 大流行停止了 NASH 患者新藥臨床試驗的招募，但人們轉向了虛擬就診等替代資料收集方法。非酒精性脂肪性肝炎是脂肪肝，會導致肝臟疤痕和損傷。

目前尚無 FDA核准的NASH治療方法，在極端情況下，疾病可能會發展到患者需要進行肝臟移植的程度。 NASH 與糖尿病一樣，與肥胖和高糖飲食有關。一些製藥公司正在測試糖尿病治療是否可以幫助 NASH 患者。然而，COVID-19 大流行對 NASH 臨床試驗的各個要素提出了挑戰，從患者招募到 IP 劑量、安全監測和資料完整性。由於臨床研究監測儀無法移動，遠端電子監測是傳統現場監測的可行替代方案。監測員可以透過紙本郵件、電子郵件（允許直接存取電子健康記錄）或遠端監測系統從研究中心接收資訊。

12 月，FDA 發布指南，鼓勵製藥業開發和驗證改進的生物標記物，用於 NASH 的診斷和進展。在許多方面，與普遍缺乏對 NASH 的認知相比，切片檢查的障礙非常重要。這就是為什麼製藥公司正在投資創新技術（例如各種診斷影像技術）來減輕患者負擔，並利用積極的資料來鼓勵接受這些進展作為臨床試驗中適當的終點標誌物，關鍵是要說服 FDA。

非酒精性脂肪性肝炎臨床試驗市場報告亮點

  • III 期試驗佔據市場主導地位，2024 年佔總銷售佔有率的 54.3%。 III 期試驗對於在提交監管部門核准之前確認新治療方法的有效性和安全性至關重要。
  • 2024 年，由於越來越關注新型治療性介入的評估，介入測試領域佔據了市場主導地位。此外，越來越多的研發研究測試 NASH 的候選藥物，包括單一療法和聯合治療。
  • 2024年，北美非酒精性脂肪性肝炎臨床試驗市場佔據主導地位，佔有率為48.9%。該地區的成長歸功於其先進的醫療保健系統、龐大的患者群體和強大的研究基礎設施。
  • 亞太地區非酒精性脂肪性肝炎臨床試驗市場預計在預測期內將以最高複合年成長率成長。這種成長是由糖尿病和肥胖等代謝疾病的日益普及所推動的。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章非酒精性脂肪性肝炎臨床試驗市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章非酒精性脂肪性肝炎臨床試驗市場：階段、估計與趨勢分析

  • 細分儀表板
  • 全球非酒精性脂肪性肝炎臨床試驗市場、階段與變異分析
  • 非酒精性脂肪性肝炎臨床試驗規模及趨勢分析（分階段，2018-2030年）
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第5章非酒精性脂肪性肝炎臨床試驗市場：研究設計、估算與趨勢分析

  • 細分儀表板
  • 全球非酒精性脂肪性肝炎臨床試驗市場、研究設計變異分析
  • 非酒精性脂肪性肝炎臨床試驗規模與趨勢分析（依研究設計，2018-2030）
  • 干預研究
  • 觀察性研究
  • 擴大訪問研究

第6章 非酒精性脂肪性肝炎臨床試驗市場：區域估計與趨勢分析

  • 2024 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 公司分類
  • 2024 年企業市場分析
  • 公司簡介
    • Pfizer Inc.
    • Novartis AG
    • Icon Plc
    • Laboratory Corporation of America
    • AbbVie Inc.
    • Cadila Healthcare Ltd.
    • Takeda Pharmaceuticals
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Gilead Sciences Inc.
Product Code: GVR-4-68039-911-4

Non-alcoholic Steatohepatitis Clinical Trials Market Growth & Trends:

The global non-alcoholic steatohepatitis clinical trials market size is expected to reach USD 4.14 billion by 2030, registering a CAGR of 6.26% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising healthcare expenditure, cases of obesity, and prevalence of non-alcoholic steatohepatitis (NASH) are the factors driving the growth of this market. Due to the COVID-19 pandemic, enrollment in new drug clinical trials for NASH patients was halted, but people shifted to alternate means of data collecting methods, like virtual visits. Non-alcoholic Steatohepatitis is a fatty liver disease that causes scarring and damage to the liver.

NASH has no FDA-approved treatment and can proceed to the point where patients need a liver transplant in extreme situations. NASH, like diabetes, is linked to obesity and a high-sugar diet. Some pharmaceutical companies are testing whether diabetes drugs could help NASH patients. However, the COVID-19 pandemic has thrown a wrench into every element of NASH clinical trials, from patient recruiting to IP administration and safety monitoring to data integrity. As clinical research monitors are not allowed to travel, remote electronic monitoring is a viable alternative to traditional on-site monitoring. Monitors could receive information from research locations by paper mail, e-mail (allowing direct access to electronic medical records), or remote monitoring systems.

In December, the FDA issued guidance urging the pharmaceutical sector to develop and confirm improved biomarkers for the diagnosis and progression of NASH. In many aspects, getting past the biopsy barrier is significant compared to a lack of general awareness of NASH, that's why it is critical for pharmaceutical companies to invest in innovations (such as a variety of imaging techniques) to alleviate this patient burden, and then persuade the FDA with positive data to accept those advancements as appropriate end-point markers for clinical trials.

Non-alcoholic Steatohepatitis Clinical Trials Market Report Highlights:

  • The phase III segment dominated the market, accounting for 54.3% of the total revenue share in 2024. Phase III trials are essential for confirming the efficacy and safety of new therapies before they can be submitted for regulatory approval.
  • The interventional studies segment dominated the market in 2024 owing to an increasing focus on evaluating new therapeutic interventions. Moreover, growing research and development studies to test novel drug candidates, including both monotherapies and combination therapies for NASH.
  • North America non-alcoholic steatohepatitis clinical trials market dominated and accounted for a 48.9% share in 2024. The growth in the region is attributed to the region's advanced healthcare system, large patient population, and strong research infrastructure.
  • The non-alcoholic steatohepatitis clinical trials market in Asia Pacific is expected to grow at the highest CAGR over the forecast period. The growth can be attributed to the increasing prevalence of metabolic disorders, such as diabetes and obesity.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Non-alcoholic Steatohepatitis Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Pharmaceutical R&D Investment
      • 3.2.1.2. Rising Diabetic Population & Obesity
      • 3.2.1.3. Rising Healthcare Expenditure
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of Awareness
      • 3.2.2.2. Barriers to Enrolment
      • 3.2.2.3. Lethargic Drug Approval Process
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Non-alcoholic Steatohepatitis Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Non-alcoholic steatohepatitis clinical trials Market; Phase Movement Analysis
  • 4.3. Global Non-alcoholic Steatohepatitis Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Non-alcoholic Steatohepatitis Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Non-alcoholic Steatohepatitis Clinical Trials Market; Study Design Movement Analysis
  • 5.3. Global Non-alcoholic steatohepatitis clinical trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
  • 5.4. Interventional Studies
    • 5.4.1. Interventional studies market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Observational Studies
    • 5.5.1. Observational studies market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Expanded Access Studies
    • 5.6.1. Expanded access studies market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Non-alcoholic Steatohepatitis Clinical Trials Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. North America
    • 6.3.1. North America Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Competitive scenario
      • 6.3.2.3. Regulatory framework
      • 6.3.2.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Competitive scenario
      • 6.3.3.3. Regulatory framework
      • 6.3.3.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.4. Mexico
      • 6.3.4.1. Key country dynamics
      • 6.3.4.2. Competitive scenario
      • 6.3.4.3. Regulatory framework
      • 6.3.4.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Competitive scenario
      • 6.4.2.3. Regulatory framework
      • 6.4.2.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Competitive scenario
      • 6.4.3.3. Regulatory framework
      • 6.4.3.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Competitive scenario
      • 6.4.4.3. Regulatory framework
      • 6.4.4.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Competitive scenario
      • 6.4.5.3. Regulatory framework
      • 6.4.5.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Competitive scenario
      • 6.4.6.3. Regulatory framework
      • 6.4.6.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Competitive scenario
      • 6.4.7.3. Regulatory framework
      • 6.4.7.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Competitive scenario
      • 6.4.8.3. Regulatory framework
      • 6.4.8.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key country dynamics
      • 6.4.9.2. Competitive scenario
      • 6.4.9.3. Regulatory framework
      • 6.4.9.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Competitive scenario
      • 6.5.2.3. Regulatory framework
      • 6.5.2.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Competitive scenario
      • 6.5.3.3. Regulatory framework
      • 6.5.3.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Competitive scenario
      • 6.5.4.3. Regulatory framework
      • 6.5.4.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Competitive scenario
      • 6.5.5.3. Regulatory framework
      • 6.5.5.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Competitive scenario
      • 6.5.6.3. Regulatory framework
      • 6.5.6.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.7. Thailand
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Competitive scenario
      • 6.5.7.3. Regulatory framework
      • 6.5.7.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Competitive scenario
      • 6.6.2.3. Regulatory framework
      • 6.6.2.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Competitive scenario
      • 6.6.3.3. Regulatory framework
      • 6.6.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. MEA Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Competitive scenario
      • 6.7.2.3. Regulatory framework
      • 6.7.2.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Competitive scenario
      • 6.7.3.3. Regulatory framework
      • 6.7.3.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Competitive scenario
      • 6.7.4.3. Regulatory framework
      • 6.7.4.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Competitive scenario
      • 6.7.5.3. Regulatory framework
      • 6.7.5.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Company Market Position Analysis, 2024
  • 7.3. Company Profiles
    • 7.3.1. Pfizer Inc.
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Service benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Novartis AG
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Service benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Icon Plc
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Service benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Laboratory Corporation of America
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Service benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. AbbVie Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Service benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Cadila Healthcare Ltd.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Service benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Takeda Pharmaceuticals
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Service benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Eli Lilly and Company
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Service benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Novo Nordisk A/S
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Service benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Gilead Sciences Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Service benchmarking
      • 7.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 4 Global Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 5 Global Non-alcoholic Steatohepatitis Clinical Trials, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Non-alcoholic Steatohepatitis Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 8 North America Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 9 U.S. Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 10 U.S. Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 11 Canada Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 12 Canada Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 13 Mexico Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 14 Mexico Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 15 UK Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 16 UK Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 17 Germany Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Germany Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 19 France Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 20 France Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 21 Italy Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 22 Italy Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 23 Spain Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 24 Spain Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 25 Sweden Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 26 Sweden Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 27 Norway Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 28 Norway Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 29 Denmark Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Denmark Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 31 India Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 32 India Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 33 China Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 34 China Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 35 Japan Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Japan Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 37 India Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 38 India Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 39 Australia Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 40 Australia Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 41 Thailand Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 42 Thailand Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 43 South Korea Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 44 South Korea Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 45 Brazil Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 46 Brazil Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 47 Argentina Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 48 Argentina Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 49 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 50 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 51 UAE Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 52 UAE Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 53 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 54 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Non-alcoholic Steatohepatitis Clinical Trials, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 13 Global Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 14 Global Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 15 Global Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 16 Global Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 17 Global Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 18 Global Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 19 North America Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 20 North America Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 21 North America Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 22 North America Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 23 North America Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 24 North America Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 25 US Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 26 US Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 27 US Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 28 US Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 29 US Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 30 US Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 31 US Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 34 Canada Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 36 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 37 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 38 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 42 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 44 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 46 Europe Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 47 Europe Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 48 Europe Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 49 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 50 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 51 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 52 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 53 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 54 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 55 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 56 UK Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 57 UK Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 58 UK Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 59 UK Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 60 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 61 Germany Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 62 Germany Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 63 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 64 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 65 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 66 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 67 France Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 68 France Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 69 France Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 70 France Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 71 France Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 72 France Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 73 France Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 74 Italy Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 75 Italy Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 76 Italy Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 77 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 78 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 79 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 80 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 81 Spain Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 82 Spain Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 83 Spain Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 84 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 85 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 86 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 87 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 88 Denmark Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 89 Denmark Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 90 Denmark Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 91 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 92 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 93 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 94 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 95 Sweden Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 96 Sweden Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 97 Sweden Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 98 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 99 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 100 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 101 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 102 Norway Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 103 Norway Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 104 Norway Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 105 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 106 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 107 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 108 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 109 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 110 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 111 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 112 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 113 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 114 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 115 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 116 China Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 117 China Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 118 China Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 119 China Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 120 China Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 121 China Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 122 China Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 123 Japan Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 124 Japan Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 125 Japan Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 126 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 127 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 128 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 129 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 130 India Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 131 India Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 132 India Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 133 India Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 134 India Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 135 India Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 136 India Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 137 Australia Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 138 Australia Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 139 Australia Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 140 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 141 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 142 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 143 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 144 Thailand Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 145 Thailand Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 146 Thailand Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 147 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 148 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 149 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 150 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 151 South Korea Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 152 South Korea Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 153 South Korea Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 154 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 155 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 156 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 157 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 158 Latin America Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 159 Latin America Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 160 Latin America Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 161 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 162 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 163 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 164 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 165 Brazil Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 166 Brazil Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 167 Brazil Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 168 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 169 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 170 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 171 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 172 Argentina Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 173 Argentina Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 174 Argentina Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 175 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 176 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 177 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 178 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 179 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 180 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 181 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 182 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 183 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 184 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 185 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 186 South Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 187 South Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 188 South Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 189 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 190 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 191 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 192 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 193 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 194 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 195 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 196 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 197 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 198 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 199 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 200 UAE Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 201 UAE Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 202 UAE Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 203 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 204 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 205 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 206 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 207 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 208 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 209 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 210 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 211 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 212 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 213 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)